Biogen's Tecfidera gets NICE's final nod; Novo Nordisk buys biotech plant in NH;

@FiercePharma: Top-read in FP yesterday: Galena says goodbye to ex-CEO, no severance pay included. Article | Follow @FiercePharma

@EricPFierce: Have you seen Armenian Nuritsa Grigoryan, the FDA wants know? She fled just ahead of prison. More | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: China's Luye Pharma founder soars into pharma's billionaire echelon. Story | Follow @CarlyHFierce

> The U.K.'s cost-effectiveness watchdogs gave their final blessing to Biogen Idec's ($BIIB) multiple sclerosis pill Tecfidera. Report

> Novo Nordisk ($NVO) snapped up a production facility in New Hampshire from Olympus Biotech, planning to turn out active pharmaceutical ingredients there. Report

> GlaxoSmithKline ($GSK) nabbed a new indication in the U.S. for Promacta, its blood disorder drug, for patients with a rare bone marrow problem. Report

> The National Institutes of Health released its latest "priority" list of drugs it wants drugmakers to study in children. Report

> Merck Serono has broken ground on its new pharma manufacturing facility in China, which will be the company's second-largest plant on the globe. Release

> South Africa's health department is rewriting rules for drug marketing, aiming to close loopholes that allow "perverse incentives" to influence prescribing. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Researchers develop implant/app combo to monitor glaucoma in aging eyes. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Sci gets bad news on four of 23,000+ vaginal mesh lawsuits. Article | Follow @VarunSaxena2

@EmilyWFierce: Hot on the M&A trail, Medtronic acquires NGC Medical to expand its hospital-services offerings. More from the WSJ | Follow @EmilyWFierce

> Study finds robotic prostate removal surgery results in faster recovery times. Article

> Xprize seeks Star Trek's tricorder in $10M mobile diagnostics competition. More

> Mobile medical app provider reels in $25M to expand innovative monitoring system. Story

Biotech News

@FierceBiotech: What's the #1 biotech hub for VCs? (It's still not Boston). Report | Follow @FierceBiotech

@JohnCFierce: So now we have multiple stories that Novo isn't interested in big deals. It's not a surprise. More from the WSJ | Follow @JohnCFierce

@EmilyMFierce: Thymus gland grown from reprogrammed cells in lab. FierceBiotech Research story | Follow @EmilyMFierce

> Thinking 'big,' Arch Venture gathers a $400M-plus fund to back a new wave of biotechs. Story

> Parkinson's player Civitas Therapeutics files for an $86M IPO. More

> After a string of gene therapy licensing deals, ReGenX says it's time to shine. Article

Drug Delivery News

> Fresenius Kabi receives FDA approval of three-chamber bag for parenteral nutrition. Article

> Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. Story

> Vascular device drug delivery company surpasses VC goal. More

> Louisiana Tech researchers use 3-D printing to create bioresorbable drug delivery system. Report

> PharmaJet secures FDA approval for jet injection system for flu vaccine. Article

Diagnostics News

> Flagship Biosciences and Sarepta will automate muscular dystrophy biomarker detection. Story

> FDA signs off on highly specific Type 1 diabetes biomarker test. Report

> Roche's Ventana expands infrastructure in Arizona. More

> UCLA, Harvard and others identify possible TB biomarker. Story

> Illumina, AstraZeneca, Janssen and Sanofi to pursue universal companion Dx test. Article

Pharma Marketing News

> Who's doing the mobile app dance right? Only a few in pharma, report says. Story

> Big Pharma, Big Biotech prepare for showdown in next-gen psoriasis market. Report

> Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C. News

> PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready. Article

> Listen to celebrity drug ads? Patients do hear, but they don't obey. More

And Finally... A London judge said UBS had the right to fire an analyst who chatted with a hedge fund friend about rumors relating to a Sanofi ($SNY) drug. Report

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.